Kairos Pharma jumps on prostate cancer trial data

Kairos Pharma

15/07/2025 16:25

** Shares of drug developer Kairos Pharma KAPA.A surge 77% to near 5-month high of $1.21

** Stock set for its best day in about 6 months, if gains hold

** Co says its experimental cancer therapy, ENV-105, was well tolerated in patients with advanced prostate cancer in an ongoing mid-stage study

** ENV-105 was tested in combination with standard hormone therapy, apalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), a condition where tumors grow despite hormone-blocking treatments

** Co expects to release interim efficacy data from the trial in Sept

** More than 182 million shares traded, 154 times their 25-day moving avg

** Including session moves, stock down 20% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))